PL366216A1 - Związki terapeutyczne i sposoby ich wykorzystaniaw modulowaniu angiogenezy - Google Patents
Związki terapeutyczne i sposoby ich wykorzystaniaw modulowaniu angiogenezyInfo
- Publication number
- PL366216A1 PL366216A1 PL01366216A PL36621601A PL366216A1 PL 366216 A1 PL366216 A1 PL 366216A1 PL 01366216 A PL01366216 A PL 01366216A PL 36621601 A PL36621601 A PL 36621601A PL 366216 A1 PL366216 A1 PL 366216A1
- Authority
- PL
- Poland
- Prior art keywords
- angiogenesis
- modulation
- methods
- therapeutic agents
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/704,251 US6548477B1 (en) | 2000-11-01 | 2000-11-01 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US09/972,772 US7037890B2 (en) | 2000-11-01 | 2001-10-05 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
PL366216A1 true PL366216A1 (pl) | 2005-01-24 |
Family
ID=27107287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL01366216A PL366216A1 (pl) | 2000-11-01 | 2001-11-01 | Związki terapeutyczne i sposoby ich wykorzystaniaw modulowaniu angiogenezy |
Country Status (11)
Country | Link |
---|---|
US (3) | US7084108B2 (pl) |
EP (1) | EP1330447A2 (pl) |
JP (1) | JP4212356B2 (pl) |
CN (1) | CN1505617A (pl) |
AU (3) | AU2002239479B2 (pl) |
BR (1) | BR0115109A (pl) |
CA (1) | CA2426703C (pl) |
MX (1) | MXPA03003775A (pl) |
NO (1) | NO20031978L (pl) |
PL (1) | PL366216A1 (pl) |
WO (1) | WO2002042295A2 (pl) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030190644A1 (en) | 1999-10-13 | 2003-10-09 | Andreas Braun | Methods for generating databases and databases for identifying polymorphic genetic markers |
US7105482B2 (en) | 2000-11-01 | 2006-09-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
MXPA03003775A (es) * | 2000-11-01 | 2003-07-28 | Praecis Pharm Inc | Peptidos como inhibidores de met-ap2. |
US6919307B2 (en) * | 2000-11-01 | 2005-07-19 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US6548477B1 (en) * | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
CA2480809A1 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
JP4514455B2 (ja) * | 2002-04-11 | 2010-07-28 | チルドレンズ メディカル センター コーポレーション | Tnp−470ポリマー複合体及びその使用 |
US8691780B2 (en) * | 2005-02-17 | 2014-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby |
DE102005040211B4 (de) * | 2005-08-16 | 2010-02-11 | Maquet Cardiopulmonary Ag | Verwendung von nichtionischen Estern in einer Beschichtung für mit Blut in Kontakt kommende Oberflächen und medizinische Vorrichtung |
US20070254843A1 (en) * | 2006-04-18 | 2007-11-01 | Praecis Pharmaceuticals Incorporated | Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors |
WO2008066641A2 (en) * | 2006-11-06 | 2008-06-05 | Praecis Pharmaceuticals Incorporated | Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors |
AU2008268262C1 (en) | 2007-06-26 | 2015-02-19 | Children's Medical Center Corporation | MetAP-2 inhibitor polymersomes for therapeutic administration |
EA020251B1 (ru) * | 2007-11-28 | 2014-09-30 | Мерсана Терапьютикс, Инк. | Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина |
KR100999044B1 (ko) | 2008-03-26 | 2010-12-09 | 한국원자력연구원 | 킬레이트제 접합 α-MSH 펩타이드 유도체, 이의제조방법 및 이를 유효성분으로 함유하는 흑색종 진단 및치료용 조성물 |
AU2009270799B2 (en) | 2008-07-18 | 2016-05-19 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
JP5890312B2 (ja) | 2009-10-09 | 2016-03-22 | ザフゲン,インコーポレイテッド | 肥満治療に用いられるスルホン化合物 |
EP2521719B1 (en) | 2010-01-08 | 2015-07-29 | Zafgen, Inc. | Fumagillol type compounds and methods of making and using same |
WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
WO2011088055A2 (en) | 2010-01-12 | 2011-07-21 | Zafgen Corporation | Methods and compositions for treating cardiovascular disorders |
US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
AU2011281037B2 (en) | 2010-07-22 | 2014-11-27 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
UA111479C2 (uk) | 2010-11-09 | 2016-05-10 | Зафджен, Інк. | Кристалічні форми інгібітору metap-2 та способи їх отримання і застосування |
US20140073691A1 (en) | 2010-11-10 | 2014-03-13 | Zafgen, Inc. | Methods and composition for Treating Thyroid Hormone Related Disorders |
CA2819251A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
US20130316994A1 (en) | 2010-11-29 | 2013-11-28 | Zafgen, Inc. | Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors |
US9189078B2 (en) | 2010-12-20 | 2015-11-17 | Apple Inc. | Enhancing keycap legend visibility with optical components |
CN103402989B (zh) | 2011-01-26 | 2016-04-06 | 扎夫根股份有限公司 | 四唑化合物及其制备和使用方法 |
BR112013023056A2 (pt) | 2011-03-08 | 2018-10-09 | Zafgen Inc | derivados de oxaespiro [2,5] octano e análogos |
CA2835195A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
MX345535B (es) | 2011-05-06 | 2017-02-03 | Zafgen Inc | Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso. |
EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
BR112014017673A8 (pt) | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
JP2015509102A (ja) | 2012-01-18 | 2015-03-26 | ザフゲン,インコーポレイテッド | 三環式スルホン化合物並びにその作製および使用方法 |
CA2872649A1 (en) | 2012-05-07 | 2013-11-14 | Zafgen, Inc. | Polymorphic salt of the oxalate salt of 6-o-(4-dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same |
BR112014028041A2 (pt) | 2012-05-08 | 2017-06-27 | Zafgen Inc | tratamento de obesidade hipotalâmica com inibidores de metap2 |
AU2013259620B2 (en) | 2012-05-09 | 2017-05-18 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
WO2014071363A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
AU2013337288A1 (en) | 2012-11-05 | 2015-05-21 | Zafgen, Inc. | Tricyclic compounds for use in the treatment and/or control of obesity |
EA028367B1 (ru) | 2012-11-05 | 2017-11-30 | Зафджен, Инк. | Способы лечения заболеваний печени |
CN105228610A (zh) | 2013-03-14 | 2016-01-06 | 扎夫根股份有限公司 | 治疗肾疾病和其它病症的方法 |
TW201636342A (zh) | 2014-12-19 | 2016-10-16 | 武田藥品工業有限公司 | 煙黴醇衍生物 |
CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
WO2019118612A1 (en) * | 2017-12-12 | 2019-06-20 | Zafgen, Inc. | Targeting compounds |
WO2023156996A1 (en) * | 2022-02-16 | 2023-08-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Metap2 inhibitors and uses thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2546163B1 (fr) | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application |
US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
US4954496A (en) * | 1988-08-12 | 1990-09-04 | Fujisawa Pharmaceutical Company, Ltd. | Cyclohexane derivatives and pharmaceutical compositions |
US5053461A (en) | 1988-08-31 | 1991-10-01 | Mitsubishi Rayon Co., Ltd. | Preparation method of comb copolymer, acrylic comb copolymer, and impact resistant resin composition |
CA1329771C (en) | 1988-09-01 | 1994-05-24 | Shoji Kishimoto | Angiogenesis inhibitory agent |
US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
ATE150750T1 (de) | 1988-09-01 | 1997-04-15 | Takeda Chemical Industries Ltd | Fumagillol-derivate |
DE69001187T2 (de) | 1989-03-06 | 1993-07-08 | Takeda Chemical Industries Ltd | 6-epifumagillole, ihre herstellung und ihre verwendung. |
US6017954A (en) * | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
JPH06157344A (ja) | 1992-02-07 | 1994-06-03 | Childrens Medical Center Corp:The | 血管新生阻害のための医薬製剤及び血管新生阻害方法 |
DE69311278T2 (de) * | 1992-12-16 | 1997-10-30 | Takeda Chemical Industries Ltd | Stabile pharmazeutische Zubereitung mit Fumagillolderivaten |
EP0658342B1 (en) | 1993-09-24 | 1999-03-17 | Takeda Chemical Industries, Ltd. | Antineoplastic pharmaceutical composition containing a fumagillol derivative and a platinum complex |
JP2923736B2 (ja) * | 1994-08-18 | 1999-07-26 | 春日電機株式会社 | 多段階操作インタ−ロック付押釦開閉器 |
FR2733498B1 (fr) | 1995-04-27 | 1997-05-30 | Adir | Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP0799616A1 (en) * | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
CA2264227A1 (en) * | 1996-09-27 | 1998-04-02 | Raymond A. Firestone | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
WO1998056372A1 (en) | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
CA2302551C (en) | 1997-09-10 | 2005-02-08 | Meiji Seika Kaisha, Ltd. | .beta.-fructofuranosidase and its gene |
WO1999061432A1 (en) * | 1998-05-12 | 1999-12-02 | Biochem Pharma Inc. | Fumagillin analogs and their use as angiogenesis inhibitors |
KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
US6584477B1 (en) | 1999-02-04 | 2003-06-24 | Hewlett Packard Development Company, L.P. | High speed system and method for replicating a large database at a remote location |
AU772074B2 (en) * | 1999-04-28 | 2004-04-08 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
CA2370245A1 (en) * | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
MXPA03003775A (es) * | 2000-11-01 | 2003-07-28 | Praecis Pharm Inc | Peptidos como inhibidores de met-ap2. |
US6919307B2 (en) * | 2000-11-01 | 2005-07-19 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US7105482B2 (en) * | 2000-11-01 | 2006-09-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
-
2001
- 2001-11-01 MX MXPA03003775A patent/MXPA03003775A/es active IP Right Grant
- 2001-11-01 CN CNA018214142A patent/CN1505617A/zh active Pending
- 2001-11-01 AU AU2002239479A patent/AU2002239479B2/en not_active Ceased
- 2001-11-01 CA CA002426703A patent/CA2426703C/en not_active Expired - Fee Related
- 2001-11-01 JP JP2002544429A patent/JP4212356B2/ja not_active Expired - Fee Related
- 2001-11-01 PL PL01366216A patent/PL366216A1/pl unknown
- 2001-11-01 WO PCT/US2001/046086 patent/WO2002042295A2/en active IP Right Grant
- 2001-11-01 BR BR0115109-6A patent/BR0115109A/pt not_active IP Right Cessation
- 2001-11-01 US US10/001,945 patent/US7084108B2/en not_active Expired - Fee Related
- 2001-11-01 EP EP01987241A patent/EP1330447A2/en not_active Withdrawn
- 2001-11-01 AU AU3947902A patent/AU3947902A/xx active Pending
-
2003
- 2003-04-30 NO NO20031978A patent/NO20031978L/no unknown
-
2005
- 2005-09-27 US US11/238,152 patent/US7268111B2/en not_active Expired - Fee Related
-
2006
- 2006-03-24 US US11/388,767 patent/US7405194B2/en not_active Expired - Fee Related
- 2006-12-21 AU AU2006252316A patent/AU2006252316A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002042295A2 (en) | 2002-05-30 |
AU2002239479B2 (en) | 2006-11-09 |
US20060069028A1 (en) | 2006-03-30 |
EP1330447A2 (en) | 2003-07-30 |
AU3947902A (en) | 2002-06-03 |
US20020151493A1 (en) | 2002-10-17 |
US7405194B2 (en) | 2008-07-29 |
NO20031978D0 (no) | 2003-04-30 |
CA2426703A1 (en) | 2002-05-30 |
US7268111B2 (en) | 2007-09-11 |
JP2004531466A (ja) | 2004-10-14 |
CN1505617A (zh) | 2004-06-16 |
MXPA03003775A (es) | 2003-07-28 |
JP4212356B2 (ja) | 2009-01-21 |
WO2002042295A3 (en) | 2003-02-20 |
BR0115109A (pt) | 2005-10-18 |
US20060223758A1 (en) | 2006-10-05 |
AU2006252316A1 (en) | 2007-01-25 |
NO20031978L (no) | 2003-06-11 |
US7084108B2 (en) | 2006-08-01 |
CA2426703C (en) | 2005-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3947902A (en) | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | |
GB0111872D0 (en) | Therapeutic agents and methods | |
EP1283702A4 (en) | MEDICAL ASSOCIATION ARRANGEMENT AND METHOD OF THE APPLICATION | |
GB0012671D0 (en) | Therapeutic agents | |
GB0003397D0 (en) | Therapeutic agents | |
GB0004003D0 (en) | Therapeutic agents | |
GB0018473D0 (en) | Therapeutic agents | |
AU6118001A (en) | Combination therapeutic compositions and methods of use | |
MXPA02004770A (es) | Composiciones terapeuticas y metodos para su uso. | |
GB0017256D0 (en) | Therapeutic agents | |
GB0027561D0 (en) | Therapeutic agents | |
GB0005789D0 (en) | Therapeutic agents | |
GB0007907D0 (en) | Therapeutic agents | |
GB0012214D0 (en) | Therapeutic agents | |
GB0003254D0 (en) | Heterocyclic compounds and their therapeutic use | |
GB0008696D0 (en) | Therapeutic agents | |
GB0000564D0 (en) | Therapeutic agents | |
GB0023610D0 (en) | Therapeutic agents | |
GB0020721D0 (en) | Therapeutic agents | |
GB0017518D0 (en) | Therapeutic agents | |
PL363048A1 (pl) | Kompozycje farmaceutyczne i sposoby ich stosowania | |
AU5565401A (en) | Materials and methods for the treatment of depression | |
IL151493A0 (en) | Use of dermaciclane for the treatment of anxiety and depression | |
GB0018887D0 (en) | Compound and their therapeutic use | |
GB0017543D0 (en) | Therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |